Special Investigation Of Xalkori For Nsclc (Regulatory Post Marketing Commitment Plan)
Phase of Trial: Phase IV
Latest Information Update: 20 Feb 2017
At a glance
- Drugs Crizotinib (Primary)
- Indications Non-small cell lung cancer
- Focus Adverse reactions
- Sponsors Pfizer
- 15 Feb 2017 Status changed from active, no longer recruiting to completed.
- 17 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Oct 2016.
- 17 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Oct 2016.